Table 3.
Supplemental medication use and complications in the different study groups.*
| Group 1 | Group 2 | Group 3 | P value | |
|---|---|---|---|---|
| Nausea/vomiting | 28 (80) | 8 (22.85) | 20 (57.14) | < 0.0001 |
| Irritation | 7 (20) | 3 (8.57) | 2 (5.71) | 0.155 |
| Respiratory complications | 5 (14.28) | 3 (8.57) | 4 (11.42) | 0.754 |
| Vasopressor requirement | 4 (11.42) | 18 (51.42) | 7 (20) | 0.0004 |
| Atropine requirement | 0 (0) | 0 (0) | 0 (0) | |
| Hypotension | 25 (69.4) | 24 (68.6) | 24 (68.6) | 0.996 |
| Bradycardia | 3 (8.57) | 3 (8.57) | 0 (0) | 0.203 |
⁎
Group 1: Intrathecal bupivacaine-sufentanil, Group 2: Intrathecal bupivacaine-fentanyl, and group 3: Intrathecal bupivacaine + intravenous acetaminophen-morphine-fentanyl. Values are presented as n (%).